CoChat
Sign Up
Cited by 6Renal Transplantation Outcomes and TreatmentsChronic Kidney Disease and DiabetesInflammation biomarkers and pathways

Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients

Open access
Jehn, Ulrich, Schütte-Nütgen, Katharina, Henke, Ute, Pavenstädt, Hermann, Suwelack, Barbara, Reuter, Stefan·2021·Scientific Reports
DOI 10.1038/s41598-021-83333-7PMC PMC7880993

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

The prognostic significance of suPAR in various kidney diseases has recently been demonstrated. Its role in transplantation-specific outcomes is still largely unknown. Therefore, we prospectively investigated the prognostic relevance of suPAR in patients before and one year after kidney transplantation (KTx). We included 100 patients who had received a kidney transplantation between 2013 and 2015. The plasma concentration of suPAR was measured by ELISA assay. In recipients of living donations (LD), pre-transplant suPAR levels were significantly lower than those of recipients of deceased donations (DD). After KTx, suPAR levels significantly declined in LD and DD recipients, without a detectable difference between both groups any more. Higher suPAR levels in recipients one year after KTx were associated with a more severe eGFR loss in the following three years in multivariable cox-regression (n = 82, p = 0.021). suPAR-levels above 6212 pg/ml one year after KTx are associated with eGFR loss > 30%, which occurred almost twice as fast as in patients with suPAR ≤ 6212 pg/ml (p < 0.001). Hence, suPAR level at one year mark might be a risk indicator of increased eGFR loss.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-021-83333-7

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several putatively impacted proteins are potential biomarkers or drug targets (for example, suPAR and PILRA).

    “It remains challenging to establish the pervasiveness of assay-interference effects; however, we note that several putatively impacted proteins are potential biomarkers or drug targets (for example, suPAR32,33 and PILRA27).”

    From Cross-ancestry comparison of aptamer and antibody protein measures (2026) · cites this paper as [33]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 34

  1. [1]Hahm E Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease Nat. Med. 2017 23 100 106 10.1038/nm.4242 27941791 PMC5405698 · DOI
  2. [2]Thunø M Macho B Eugen-Olsen J suPAR: The molecular crystal ball Dis. Markers 2009 27 157 172 10.1155/2009/504294 19893210 PMC3835059 · DOI
  3. [3]Gussen H Neutrophils are a main source of circulating suPAR predicting outcome in critical illness J. Intensive Care 2019 7 26 10.1186/s40560-019-0381-5 31061709 PMC6487050 · DOI
  4. [4]Wei C uPAR isoform 2 forms a dimer and induces severe kidney disease in mice J. Clin. Investig. 2019 129 1946 1959 10.1172/JCI124793 30730305 PMC6486353 · DOI
  5. [5]Wei C Modification of kidney barrier function by the urokinase receptor Nat. Med. 2008 14 55 63 10.1038/nm1696 18084301 · DOI
  6. [6]Yoo T-H Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease J. Am. Soc. Nephrol. JASN 2015 26 133 147 10.1681/ASN.2013111213 24925721 PMC4279736 · DOI
  7. [7]Wei C Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat. Med. 2011 17 952 960 10.1038/nm.2411 21804539 PMC4089394 · DOI
  8. [8]Alachkar N Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy Transplantation 2013 96 649 656 10.1097/TP.0b013e31829eda4f 23842190 PMC4026282 · DOI
  9. [9]Hayek SS Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease J. Am. Soc. Nephrol. JASN 2019 30 1305 1313 10.1681/ASN.2018121227 31171572 PMC6622421 · DOI
  10. [10]Hayek SS Soluble urokinase receptor and chronic kidney disease N. Engl. J. Med. 2015 373 1916 1925 10.1056/NEJMoa1506362 26539835 PMC4701036 · DOI
  11. [11]Torino C Soluble urokinase plasminogen activator receptor (suPAR) and all-cause and cardiovascular mortality in diverse hemodialysis patients Kid. Int. Rep. 2018 3 1100 1109 10.1016/j.ekir.2018.05.004 PMC6127402 30197976 · DOI
  12. [12]Drechsler C Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on hemodialysis Clin. J. Am. Soc. Nephrol. CJASN 2017 12 1265 1273 10.2215/CJN.10881016 28495863 PMC5544516 · DOI
  13. [13]Saylam KG Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity Int. J. Rheumat. Dis. 2018 21 866 870 10.1111/1756-185X.12873 27171829 · DOI
  14. [14]Pliyev BK Menshikov MY Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis Inflammation 2010 33 1 9 10.1007/s10753-009-9152-0 19756998 · DOI
  15. [15]Geboers DGPJ Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients Intensive Care Med. 2015 41 1281 1290 10.1007/s00134-015-3924-9 26100127 · DOI
  16. [16]Liu KL Fan JH Wu J Prognostic role of circulating soluble uPAR in various cancers: A systematic review and meta-analysis Clin. Lab. 2017 63 871 880 28627814
  17. [17]Winnicki W Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method Sci. Rep. 2019 9 13783 10.1038/s41598-019-50405-8 31551522 PMC6760112 · DOI
  18. [18]Harel E Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation Clin. Transplant. 2019 33 e13487 10.1111/ctr.13487 30689221 · DOI
  19. [19]Alachkar N Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab BMC Nephrol. 2018 361 2 PMC6296111 30558559
  20. [20]Levey AS A new equation to estimate glomerular filtration rate Ann. Intern. Med. 2009 150 604 612 10.7326/0003-4819-150-9-200905050-00006 19414839 PMC2763564 · DOI · Paper page
  21. [21]Jehn U Prognostic value of growth differentiation factor 15 in kidney donors and recipients J. Clin. Med. 2020 9 2 PMC7291214 32375259
  22. [22]Mengel M Sis B Halloran PF SWOT analysis of Banff: strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathology Am. J. Transpl. 2007 7 2221 2226 10.1111/j.1600-6143.2007.01924.x 17848174 · DOI
  23. [23]Levey AS GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the national kidney foundation and the US food and drug administration Am. J. Kidney Dis. 2014 64 821 835 10.1053/j.ajkd.2014.07.030 25441437 · DOI · Paper page
  24. [24]Mol PGM Maciulaitis R Vetter T GFR decline as an end point for clinical trials in CKD: A view from Europe Am. J. Kidney Dis. 2014 64 838 840 10.1053/j.ajkd.2014.10.001 25455092 · DOI
  25. [25]Hayek SS Soluble urokinase receptor and acute kidney injury N. Engl. J. Med. 2020 382 416 426 10.1056/NEJMoa1911481 31995687 PMC7065830 · DOI
  26. [26]Saleem MA What is the role of soluble urokinase-type plasminogen activator in renal disease? Nephron 2018 139 334 341 10.1159/000490118 29909410 · DOI
  27. [27]Franco Palacios CR Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates Transplantation 2013 96 394 399 10.1097/TP.0b013e3182977ab1 23736353 PMC4119827 · DOI
  28. [28]Hart A OPTN/SRTR 2017 annual data report: Kidney Am. J. Transpl. 2019 19 Suppl 2 19 123 10.1111/ajt.15274 30811893 · DOI
  29. [29]Reuter S A comparison of different algorithms for the assessment of cardiovascular risk in patients at waiting list for kidney transplantation PLoS ONE 2016 11 e0161927 10.1371/journal.pone.0161927 27768693 PMC5074508 · DOI
  30. [30]Chew-Harris J Appleby S Richards AM Troughton RW Pemberton CJ Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals Clin. Biochem. 2019 69 36 44 10.1016/j.clinbiochem.2019.05.010 31129182 · DOI
  31. [31]Faul C The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A Nat. Med. 2008 14 931 938 10.1038/nm.1857 18724379 PMC4109287 · DOI
  32. [32]Fu J Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis Kidney Int. 2018 93 416 429 10.1016/j.kint.2017.08.031 29102373 · DOI
  33. [33]KDIGO clinical practice guideline for the care of kidney transplant recipients. American journal of transplantation9, S1–155 (2009). 19845597
  34. [34]Ferguson TW Komenda P Tangri N Cystatin C as a biomarker for estimating glomerular filtration rate Curr. Opin. Nephrol. Hypertens. 2015 24 295 300 10.1097/MNH.0000000000000115 26066476 · DOI

Cited by

Sorted by citations

Authors
Jehn, U., Schütte-Nütgen, K., Henke, U., Pavenstädt, H., Suwelack, B., & Reuter, S.
Affiliations
University Hospital Münster (DE)
Corresponding author
Jehn, Ulrich
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2021-02-12
Volume
11
Issue
1
Pages
3713-3713
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-021-83333-7
PMC
PMC7880993
OpenAlex
W3112810656
Cited by
6
References
0
Citations by year
2026: 2 · 2024: 1 · 2022: 2 · 2021: 1
FWCI
0.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • URN:NBN Resolver for Germany & Switzerland (German National Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Universitäts- und Landesbibliothek Münster (cc-by)
Funders
  • Innovative Medizinische Forschung (IMF), Medical faculty, University of Muenster
  • Projekt DEAL
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
soluble urokinase plasminogen activator receptor, suPAR, kidney transplantation, estimated glomerular filtration rate decline, renal function decline, prognostic factors, living donor transplantation, deceased donor transplantation
MeSH terms
Adult, Aged, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Postoperative Complications, Prospective Studies, Biomarkers, Kidney Transplantation, Renal Insufficiency, Receptors, Urokinase Plasminogen Activator

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review